Biotech News

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.2026-10-14 20:30 ESTConference / presentation

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on

Related news

CHRSCoherus BioSciences, Inc.2026-09-23 13:30 EST

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Coherus BioSciences, Inc.

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied...

Recent company news

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

CHRSCoherus BioSciences, Inc.2026-09-23 13:30 EST

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close: 1.02 USD
Market cap: 234.46M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States